Amneal Biosciences shall focus specifically on the commercialization of high-barrier-to-entry generic and specialty pharmaceuticals such as injectables, oncologics and biosimilars to globally healthcare providers. Having a dedicated company focused on the unique requirements and logistics of this market segment allows Amneal to ensure the same quality level and service to healthcare institutions and experts that we deliver to our existing retail customers, explains Amneal co-CEO and Chairman Chirag Patel need to contact the doctor . Amneal includes a robust pipeline of both small-molecule injectable generics and also biosimilars, and we be prepared to bring the to begin these to advertise in early 2016.